Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer

J Feliu, C Castañón, A Salud, J R Mel, P Escudero, A Pelegrín, L López-Gómez, M Ruiz, E González, F Juárez, J Lizón, J Castro, M González-Barón, Oncopaz Cooperative Group, Spain, J Feliu, C Castañón, A Salud, J R Mel, P Escudero, A Pelegrín, L López-Gómez, M Ruiz, E González, F Juárez, J Lizón, J Castro, M González-Barón, Oncopaz Cooperative Group, Spain

Abstract

The purpose of this phase II randomised trial was to determine which of two schemes, raltitrexed-irinotecan or raltitrexed-oxaliplatin, offered better activity and less toxicity in patients with advanced colorectal cancer (CRC). A total of 94 patients with previously untreated metastatic CRC were included and randomised to receive raltitrexed 3 mg m(-2) followed by oxaliplatin 130 mg m(-2) on day 1 (arm A), or CPT-11 350 mg m(-2) followed by raltitrexed 3 mg m(-2) (arm B). In both arms treatment was repeated every 3 weeks. Intent-to-treat (ITT) analysis showed an overall response rate of 46% (95% CI, 29.5-57.7%) for arm A, and 34% (95% CI, 19.8-48.4%) for arm B. Median time to progression was 8.2 months for arm A and 8.8 months for arm B. After a median follow-up of 14 months, 69% of patients included in arm A were still alive, compared to 59% of those included in arm B. Overall, 31 patients (65%) experienced some episode of toxicity in arm A and 32 patients (70%) in arm B, usually grade 1-2. The most common toxicity was hepatic, with 29 patients (60%) in arm A and 24 patients (62%) in arm B, and was grade 3-4 in four (8%) and four (9%) patients, respectively. In all, 14 patients (29%) from arm A and 24 patients (52%) from arm B had some grade of diarrhoea (P<0.03). Neurologic toxicity was observed in 31 patients (64%) in arm A, and was grade 3-4 in five patients (10%), while a cholinergic syndrome was detected in nine patients (19%) in arm B. There were no differences in haematologic toxicity. One toxic death (2%) occurred in arm A and three (6.5%) in arm B. In conclusion, both schemes have high efficacy as first-line treatment in metastatic CRC and their total toxicity levels are similar. Regimens with raltitrexed seem a reasonable alternative to fluoropyrimidines.

References

    1. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR (1988) Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323–1330
    1. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A (2002) Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13: 1424–1429
    1. Cascinu S, Graziano F, Fearrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Batteli N, Sierna S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R (2002) Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 13: 716–720
    1. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084–2091
    1. Clark DR, Raffin TA (1990) Infectious complications of indwelling long-term central venous catheters. Chest 97: 966–972
    1. Cocconi G, Cunningham D, Van Custem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized multicenter trial of raltitrexed vs fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16: 2943–2952
    1. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
    1. Cunningham D, Zalckberg JR, Smith IE (1994) ‘Tomudex’: a novel thymidilate synthase (TS) inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 5(Suppl 8): 179 (abstr 904)
    1. Cunningham D, Zalckberg JR, Rath U, Olver I, Van Custem E, Svensson C, Seitz JF, Haper P, Kerr D, Perez-Manga G (1995) ‘Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31: 1945–1954
    1. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
    1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047
    1. Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, López-Tejada MR, Rodríguez-García JM, Martínez MP, Sanz M, Sánchez JJ, González-Barón M (2004) Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer 90: 1502–1507
    1. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitovich F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levy F (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136–147
    1. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30
    1. Grávalos C, García-Girón C, León AI, Salud A, Esteban B, Sevilla I, Maurel J, Murias A, García-Rico E, Cortés-Funes HG (2005) TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): preliminary results of a multicenter randomized phase II trial. Proc Am Soc Clin Oncol 22: 269 (abstr 3599)
    1. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzscmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21: 129 (abstr 512)
    1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214
    1. Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23: 255–278
    1. Judson I, Maughan TS, Beale P, Primrose J, Hoskin P, Hawell J, Berry C, Walker M, Sutcliffe F (1998) Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex, ZD1694). Br J Cancer 78: 118–1193
    1. Keller OR, Vincent M, Maroun J, Fields A, Wasil T, Moore M, Dahrouge S, Donker R, Douglas L, Abugaber AA, Donnelly J (2001) Folate depletion is associated with significant haematological toxicity in patients treated with raltitrexed (Tomudex) for colorectal cancer. Proc Am Soc Clin Oncol 20: 141 (abstr 562)
    1. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 145–146
    1. Maughan TS, James RD, Kerr DJ, Lederrmann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ (2002) British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet 359: 1555–1563
    1. Pazdur R, Vicent M (1997) Raltitrexed (Tomudex) vs 5-fluorouracil and leucovorin (5FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16: 228 (abstr 801)
    1. Prandoni P, Bernardi E (1999) Upper extremity deep vein thrombosis. Curr Opin Pulmon Med 5: 222–226
    1. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidine synthase inhibitor (AG 337) in human colon, breast and ovarian cancers. Anti-cancer Drugs 8: 876–885
    1. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801–3807
    1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905–914
    1. Santini D, Massacesi C, D'Agelillo RM, Marcucci F, Campisi C, Vincenzi B, Pilone A, Bianco V, Bonsignori M, Tonini G (2004) Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase II study. Med Oncol 21: 59–66
    1. Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T, Raoul JL, Becouarn Y, Bertheault-Cvitkovic F, Ychou M, Nasca S, Fandi a, Barthelemy P, Douillard JY (2002) Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 13: 1072–1079
    1. Simon R, Wittes EE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375–1381
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
    1. Tournigand C, André T, Achille E, Lledo G, Flesh M, mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22: 229–237
    1. Van Custem E, Cunningham D, Maroun J, Cervantes A, Glimelius B (2002) Raltitrexed: current clinical status and future directions. Ann Oncol 13: 513–522
    1. Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21: 3665–3675
    1. Young A, Topham C, Moore J, Turner J, Wardle J, Downes M, Evans V, Kay S (1999) A patient preference study comparing raltitrexed (Tomudex) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. Eur J Cancer Care 8: 154–161
    1. Zalckberg JR (1997) Overview of the tolerability of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 8(Suppl): 17–22

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다